TC BioPharm

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP

[TC BioPharm @TCBioPharm]

$TCBP Announces Grant of European #Patent for Targeting of Microbial, #Oncological, and Viral Indications using Modified Gamma Delta T Cells

https://t.co/jXHHjENZzd

[TC BioPharm @TCBioPharm]

$TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

The company is expected to reduce core operational burn by 55% when compared to 2024

https://t.co/Nhg7ODF5e2

[Benchling @benchling]

🔮 2025 is going to be a big year for #biotech. On @BBCNews, our CEO @sajithw explains why the industry is on the cusp of a faster, more automated, and #AI-driven future.

📺 Watch the full interview: https://t.co/jvgWckvVK2

[TC BioPharm @TCBioPharm]

$TCBP Announces Non-Binding Letter of Intent to #Acquire #Commercial #Stage Ophthalmic Pharmaceutical Company

https://t.co/LujJ7sDmYX

[TC BioPharm @TCBioPharm]

$TCBP @CEO_TCBioPharm to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

https://t.co/FDisyx9MD1

[TC BioPharm @TCBioPharm]

Congrats to @xiliotx, Inc. Great news to see M&A #Activity in the T-Cell space.

[TC BioPharm @TCBioPharm]

https://t.co/B7K0K8A68o

[TC BioPharm @TCBioPharm]

LIVE LOOK - @CEO_TCBioPharm Presenting on $TCBP at the #Sequire Investor Summit

[TC BioPharm @TCBioPharm]

$TCBP Announces #H5N1 Proof of Concept Studies Intention

https://t.co/3OmuKHC2Qn

[TC BioPharm @TCBioPharm]

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

https://t.co/P9DKzrYnRH

[TC BioPharm @TCBioPharm]

$TCBP Provides Update on #Acquisition Strategy and Current Targets

https://t.co/ZxxBhWJeL0

[TC BioPharm @TCBioPharm]

$TCBP Advances ACHIEVE Phase 2b Clinical Trial with #Final #Dosing of 3 Patients

https://t.co/bGI0SVNeJx

[TC BioPharm @TCBioPharm]

$TCBP Announces General Meeting of Shareholders to Approve One-Time #Shareholder #Dividend

The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the Company's stock at the close of trading on January 02, 2025.

https://t.co/RQp7y2PqB1

[TC BioPharm @TCBioPharm]

$TCBP Partners with @CareDx, Inc. to Support #ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

https://t.co/etMewB5Fbb

[TC BioPharm @TCBioPharm]

@HCWCO's newest Research Report gives $TCBP a "Buy" Rating with a $3.00 Price Target.

https://t.co/CY6j5c3Ulf

[TC BioPharm @TCBioPharm]

$TCBP Provides Quarterly Update on the #ACHIEVE (UK) #ClinicalTrial

- Positive safety data, allowing for exploration of higher TCB008 doses
- 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025

https://t.co/GWJKKhZILS

[TC BioPharm @TCBioPharm]

@ChYs618470 This is a tool used by all biotechs and most companies for capital access when there are moves in the market. Having this shelf in place allows future financings to be LESS dilutive, as there is not a signal to the market, and we can be opportunistic.

[TC BioPharm @TCBioPharm]

Our F3 filing (shelf) is NOT immediately dilutive. It's a placeholder that allows us to be opportunistic about good news with a positive market reaction. Filings, like the one we filed on Weds, are normal business practices for biotechs that are fundamental to accessing capital.

[TC BioPharm @TCBioPharm]

$TCBP appreciates being a part of the great work from the team @CGTCatapult #CellTherapy

Read the Report Here:
https://t.co/6WiC4VAV11

[TC BioPharm @TCBioPharm]

Congrats to @PoseidaThera on being acquired by @Roche. After such a long freeze, it's great to see M&A activity in the Cell Therapy Space.

https://t.co/JBwaiVX98T